Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Other Income (Expense)

Other Income (Expense) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$61M+112%
Gilead Sciences logo
Gilead SciencesGILD
$387M+86.1%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$1.64M-40.9%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$717.17K+377%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$563M-760%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$98K+45.9%

Other financials

Income statement

See full
Revenue-
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$550.99M+783%
Enterprise value$258.93M+455%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity-0.1×
Current ratio24.2×+10.3×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338029
Line itemTHREE MONTHS ENDED JUNE 30, 2026THREE MONTHS ENDED JUNE 30, 2025SIX MONTHS ENDED JUNE 30, 2026SIX MONTHS ENDED JUNE 30, 2025
Other income, net:
Interest income1,8861,5612,7983,425
Other (expense) income, net(1)(5)1(8)
Total other income, net1,8851,5562,7993,417
Net loss$(25,005)$(21,254)$(48,521)$(41,565)
Net loss per share, basic and diluted$(0.63)$(0.87)$(1.51)$(1.71)
Weighted-average common shares outstanding, basic and diluted39,413,23624,378,82332,086,53224,360,502
Comprehensive loss:

Item 1. Financial Statements

FAQ

What is Artiva Biotherapeutics, Inc.'s other income (expense)?
Artiva Biotherapeutics, Inc. (ARTV) reported other income (expense) of $1.89M in Q2 2026.
How has Artiva Biotherapeutics, Inc.'s other income (expense) changed year-over-year?
Artiva Biotherapeutics, Inc.'s other income (expense) increased by 21.1% year-over-year, from $1.56M to $1.89M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s other income (expense)?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s other income (expense) has grown at a 71.4% compound annual growth rate (CAGR), from $2.02M to $5.95M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Artiva Biotherapeutics, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude